drugset / Trial / NCT00256997

A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

NCT00256997

Phase 4 Terminated 167 enrolled Janssen-Ortho Inc., Canada
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate risperidone long-acting injection (an antipsychotic medication) versus oral antipsychotics in schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) participants with a history of being poorly compliant with taking their medication.

Timeline

Start
2006-01
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amisulpride Small molecule Oral
Comparator Aripiprazole Other / unclassified Oral
Comparator Olanzapine Small molecule Oral
Comparator Quetiapine Small molecule Oral
Subject Risperidone Other / unclassified 25 mg Intramuscular
Subject Risperidone Other / unclassified 37.5 mg Intramuscular
Subject Risperidone Other / unclassified 50 mg Intramuscular

Indications